The ECFS-CTN cannot guarantee that the information provided here is comprehensive. Please go to the ClinicalTrials.gov link for detailed and up-to-date information on study background, eligibility criteria, study design, outcome measures, study status, participating sites, sponsor contact information and timelines.

You can also contact the CTN coordinating centre for additional information: ECFS-CTN@uzleuven.be

Study Name on
ClinicalTrials.gov (link is external)
A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
Study DrugVX-659 in triple combination with tezacaftor and ivacaftor
Type of Study DrugCFTR modulator
Study TitleA Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
Study Phase3
Study SponsorVertex

Link on
clinicaltrials.gov (link is external)

https://clinicaltrials.gov/ct2/show/NCT03447249

Participating ECFS-CTN sitesPlease contact ecfs-ctn@uzleuven.be for most recent sitelist
Age12 years and older